3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
7
Pheochromocytoma
2
Paraganglioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Vipoma
1
Thymus Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Meningioma
1
Insulinoma
1
Gastrinoma
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
7
Capecitabine
7
Irinotecan
6
pembrolizumab
3
Radiotherapy
3
Oxaliplatin
3
Fluorouracil
3
Filgrastim
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Genetic Testing
2
FAPI-46
2
Etoposide
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cyclophosphamide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Unknown Primary
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn